Carrillo ER, Méndez SN, Carrillo CJR, Carrillo CLD

Language: Spanish
References: 15
Page: 191-195
PDF size: 105.22 Kb.

ABSTRACT

Syncope is associated with considerable costs to society as well as to the patient. Syncope may arise on a neurological, cardiac, or neurovascular background. Cardiac and neurological causes are evaluated by standard methods. Neurocardiogenic syncope is the most common of a group of reflex syncopes, characterized by a sudden failure of the autonomic nervous system to maintain blood pressure and sometimes heart rate at a level sufficient to maintain cerebral perfusion and consciousness. Neurocardiogenic syncope is diagnosed by tilt table testing. The treatment of neurocardiogenic syncope consists of information and instruction in reasonable precautions. In persisting cases, medical treatment or pacemaker implantation may be necessary.

REFERENCES

1. Goldschlangrer N, Epstein AE, Grubb BP. Etiologic considerations in the patient with syncope and an apparently normal heart. Arch Intern Med 2003; 163: 151-162.

2. Grubb BP, Karas B. Clinical disorders of the autonomic nervous system associated with orthostatic intolerance: an overview of classification, clinical evaluation, and management. Pacing Clin Electrophysiol 1999; 22: 798-810.

3. Linzer M, Yang EH, Estes NA, Wang P, Vorperian VR, Kapoor WN. Diagnosing syncope. 1. Value of history, physical examination, and electrocardiography: Clinical efficacy assessment project of the American College of Physicians. Ann Intern Med 1990; 126: 989-996.

4. Linzer M, Pontinen M, Gold GT, Divine GW, Felder A, Brooks WB. Impairment of physical and psychosocial function in recurrent syncope. J Clin Epidemiol 1991; 44: 1037-1043

5. Mosqueda-Garcia R, Furlan R, Tank J, Fernandez-Violante R. The elusive pathophysiology of neurally mediated syncope. Circulation 2000; 102: 2898-2906.

6. Benditt DG, Ferguson DW, Grubb BP. Tilt table testing for accessing syncope. J Am Coll Cardiol 1996; 28: 263-275.

7. Brignole M, Alboni P, Benditt D. Guidelines on management (diagnosis and treatment) of syncope. Eur Heart J 2001; 22: 1256-1306.

8. Krahn AD, Klein GJ, Yee R, Skanes AC. Randomized assessment of syncope trial: conventional diagnostic testing versus a prolonged monitoring strategy. Circulation 2001; 104: 46-51.

9. Brignole M, Croci F, Menozzi C. Isometric arm counter-pressure maneuvers to abort impending vasovagal syncope. J Am Coll Cardiol 2002; 40: 2053-2059.

10. El-Sayed H, Hainsworth R. Salt supplement increases plasma volume and orthostatic tolerance in patients with unexplained syncope. Heart 1996; 75: 134-140.

11. Brignole M. Randomized clinical trials of neurally mediated syncope. J Cardiovasc Electrophysiol 2003; 14: 64-69.

12. Ventura R, Mass R, Zeildler D. A randomized and controlled pilot trial of β-blockers for the treatment of recurrent syncope in patients with a positive or negative response to head-up tilt test. Pacing Clin Electrophysiol 2002; 25: 816-821.

13. Bloomfield DM, Sheldon R, Grubb BP, Calkins H, Sutton R. Putting it together: a new treatment algorithm for vasovagal syncope and related disorders. Am J Cardiol 1999; 84: 33-39.

14. Connolly SJ, Sheldon R, Thorpe KE. Pacemaker therapy for prevention of syncope in patients with recurrent severe vasovagal syncope: Second vasovagal pacemaker study (VPS III): a randomized trial. JAMA 2003; 289: 2224-2229.

15. Grubb BP. Neurocardiogenic Syncope. N Engl J Med 2005; 352: 1004-1010.